1. Transl Cancer Res. 2018 Aug;7(Suppl 7):S779-S786. doi:
10.21037/tcr.2018.08.11.

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and 
other kinase inhibitors.

Sehgal K(1), Patell R(1), Rangachari D(1), Costa DB(1).

Author information:
(1)Department of Medicine, Division of Hematology/Oncology, Beth Israel 
Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

DOI: 10.21037/tcr.2018.08.11
PMCID: PMC6186457
PMID: 30327756

Conflict of interest statement: Conflicts of Interest: DB Costa has consulting 
fees and honoraria from Pfizer, Astra-Zeneca and ARIAD/Takeda. The other authors 
have no conflicts of interest to declare.